CBX-12 is under clinical development by Cybrexa and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CBX-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBX-12 is under development for the treatment of solid tumors including small cell lung cancer, metastatic breast cancer and platinum-resistant ovarian cancer. The drug candidate a peptide drug conjugate (PDC) delivering exatecan. It is being developed based on peptide-based alphalex technology. It is administered through intravenous route. It was also under development for the treatment of triple-negative breast cancer and colorectal cancer.
Cybrexa is a biotechnology company that develops novel therapeutics for the treatment of oncology. Its pipeline program includes alphalex exactecam (CBX-12), alphalex MMAE (CBX-15), alphalex DM4 (CBX-13), alphalex multi-targeted DDR inhibitor (CBX-14) and others. The company develops small molecules that inhibit DNA repair and potential to induce acute levels of chemo- and radio-sensitization in solid tumors. It enhanced a peptide-based technology to develop Tumor-Specific Drugs (TSDs). Cybrexa peptides deliver small molecules across the lipid bilayers of cells that are specifically under low pH conditions. The company provides TSDs that can be used with both existing and new DNA repair inhibitors. Cybrexa is headquartered in New Haven, Connecticut, the US.
For a complete picture of CBX-12’s drug-specific PTSR and LoA scores, buy the report here.